Shared Placenta/Tumor Antigens and Maternal Immunity
共享胎盘/肿瘤抗原和母体免疫
基本信息
- 批准号:9316903
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-05-18 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAntigensBloodBreast Cancer CellCTAG1 geneCancer EtiologyCancer VaccinesCancerousCellsClinicalDataDeciduaDevelopmentDisease ProgressionEsophageal Squamous Cell CarcinomaEtiologyFetusFlow CytometryFutureGlycoproteinsHLA AntigensHistocompatibility AntigensHormonalHumanImmuneImmune responseImmune systemImmunityImmunologicsInheritedLeadLightLymphocyteMajor Histocompatibility ComplexMalignant NeoplasmsMammary NeoplasmsMediatingMedicalModelingMothersMusNew YorkNormal tissue morphologyNulliparityOvalbuminPatternPhysiologicalPlacentaPositioning AttributePredispositionPregnancyPropertyProteinsResearch PersonnelResistanceRiskRisk ReductionT cell responseT-LymphocyteTestingTherapeuticTimeTissuesTransgenic OrganismsTumor AntigensTumor ImmunityWomanWorkacronymscancer preventioncancer riskclinically relevantcohortembryo/fetus antigenexperimental studyfetalimmunogenicin vivoinsightinterestlifetime riskmalignant breast neoplasmmouse modelneoplastic cellnovelparityperipheral bloodplacenta neoplasmpregnantstem cell differentiationtheoriestrophoblasttumor
项目摘要
Project Summary/Abstract
Pregnancy impacts the maternal immune system and breast cancer risk, but whether these effects are related is unknown.
Many women are immunologically primed to fetal antigens during pregnancy due to the unique expression of paternally-
inherited antigens by the fetus. However, whether this priming has any consequence on subsequent progression of
diseases in women is unknown.
Tumor antigens are proteins that have limited expression in normal adult tissues, but are strongly expressed in many
cancers, including cancer of the breast. Because of their ability to induce immunity, there is strong scientific and medical
interest in exploiting this property for development of anti-cancer vaccines. Despite their restricted expression patterns,
several, which we call shared placenta/tumor antigens, are highly expressed in the placenta. Investigators have long
speculated that trophoblast cells and tumor cells share similarities, but the immunologic relationship between shared
placenta/tumor antigens, breast cancer, and pregnancy are completely unknown. In this proposal, we explore the
hypothesis that shared tumor/placenta antigens are immunogenic during pregnancy. These experiments serve as critical
proof of concept experiments, with which we can further explore the long term hypothesis that immune priming to shared
placenta tumor antigens during pregnancy alter breast cancer risk in parous women. To determine whether the placenta
primes the maternal immune system against shared placenta/tumor antigens, we propose the following Specific Aims:
1. Determine whether the murine maternal immune system is primed to shared tumor/placenta antigens.
2. Test women for evidence of sensitization to shared placenta/tumor antigens.
To our knowledge, this is the first time that a long-term consequence of the physiologically normal maternal immune
response to fetal antigens will be considered in light of a critical clinical problem: women's cancer. In the long-term, this
work could profoundly impact our understanding of why parity changes risk of breast cancer, and lead to insights into
novel cancer prevention and therapeutic strategies.
项目概要/摘要
怀孕会影响母体免疫系统和乳腺癌风险,但这些影响是否相关尚不清楚。
由于父系抗原的独特表达,许多女性在怀孕期间对胎儿抗原进行了免疫准备。
胎儿遗传的抗原。然而,这种启动是否会对随后的进展产生任何影响?
女性疾病尚不清楚。
肿瘤抗原是在正常成人组织中表达有限,但在许多组织中强烈表达的蛋白质。
癌症,包括乳腺癌。由于它们具有诱导免疫力的能力,具有很强的科学性和医学性。
有兴趣利用这一特性来开发抗癌疫苗。尽管它们的表达模式受到限制,
有几种抗原在胎盘中高度表达,我们称之为共享胎盘/肿瘤抗原。调查人员长期以来
推测滋养层细胞和肿瘤细胞有相似之处,但两者之间的免疫关系相同
胎盘/肿瘤抗原、乳腺癌和妊娠是完全未知的。在本提案中,我们探讨了
假设共享的肿瘤/胎盘抗原在怀孕期间具有免疫原性。这些实验起到了关键作用
概念验证实验,通过这些实验,我们可以进一步探索免疫启动共享的长期假设
怀孕期间的胎盘肿瘤抗原会改变经产妇女患乳腺癌的风险。判断是否胎盘
激发母体免疫系统对抗共同的胎盘/肿瘤抗原,我们提出以下具体目标:
1. 确定小鼠母体免疫系统是否已针对共同的肿瘤/胎盘抗原做好准备。
2. 测试女性是否有对共同胎盘/肿瘤抗原过敏的证据。
据我们所知,这是第一次发现生理正常的母体免疫的长期后果
将根据一个关键的临床问题来考虑对胎儿抗原的反应:女性癌症。从长远来看,这
这项工作可能会深刻影响我们对为什么胎次会改变乳腺癌风险的理解,并导致我们深入了解
新的癌症预防和治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET G PETROFF其他文献
MARGARET G PETROFF的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET G PETROFF', 18)}}的其他基金
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
- 批准号:
9979498 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
- 批准号:
10116259 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
- 批准号:
10396646 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
- 批准号:
10617856 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
- 批准号:
10215585 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
人类妊娠期对 HCV 的先天性和适应性免疫
- 批准号:
8654226 - 财政年份:2014
- 资助金额:
$ 23.25万 - 项目类别:
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
人类妊娠期对 HCV 的先天性和适应性免疫
- 批准号:
9021550 - 财政年份:2014
- 资助金额:
$ 23.25万 - 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
- 批准号:
8038448 - 财政年份:2010
- 资助金额:
$ 23.25万 - 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
- 批准号:
7774089 - 财政年份:2010
- 资助金额:
$ 23.25万 - 项目类别:
FUNCTIONAL COOPERATION BETWEEN TROPHOBLAST HLA-G AND B7 FAMILY
滋养层 HLA-G 和 B7 家族之间的功能合作
- 批准号:
7699715 - 财政年份:2008
- 资助金额:
$ 23.25万 - 项目类别:
相似国自然基金
高同型半胱氨酸血症上调B淋巴细胞抗原提呈而促进动脉粥样硬化发病
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
捻转血矛线虫H11糖蛋白抗原表位的筛选及免疫保护作用研究
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:面上项目
从SCCA2调控未折叠蛋白反应探讨凉血潜阳法对银屑病的作用机制
- 批准号:81904200
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
捻转血矛线虫诱导山羊Th9型免疫反应特点及其刺激性抗原鉴定
- 批准号:31872464
- 批准年份:2018
- 资助金额:60.0 万元
- 项目类别:面上项目
基于SEREX技术筛选的自身抗原FTL在免疫相关性全血细胞减少症中的作用研究
- 批准号:81600088
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Evaluation of growth potential of ice-free vitrified heart valves in a pediatric porcine model.
评估小儿猪模型中无冰玻璃化心脏瓣膜的生长潜力。
- 批准号:
10696568 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
An RNA vaccines systems approach to Group A streptococcus vaccine discovery
发现 A 组链球菌疫苗的 RNA 疫苗系统方法
- 批准号:
10577082 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Defining the autoimmune mechanisms driving human MOG antibody disease pathology
定义驱动人类 MOG 抗体疾病病理学的自身免疫机制
- 批准号:
10748070 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Mechanisms Regulating Inflammatory Phenotypes in Fetal Macrophages
胎儿巨噬细胞炎症表型的调节机制
- 批准号:
10750088 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别: